ASND – ascendis pharma a/s - american depositary shares (US:NASDAQ)
Stock Stats
News
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024 [Yahoo! Finance]
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Wells Fargo & Company from $260.00 to $262.00. They now have an "overweight" rating on the stock.
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $173.00 price target on the stock.
Form 6-K Ascendis Pharma A/S For: Mar 31
Form 6-K Ascendis Pharma A/S For: May 02
Form 6-K Ascendis Pharma A/S For: May 02
Form 6-K Ascendis Pharma A/S For: Apr 24
Form 6-K Ascendis Pharma A/S For: Apr 10
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.